Treatment of autonomous ovarian follicular cyst with long-term anastrozole therapy

Case report OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

Anastrozole successfully treated a recurrent autonomous ovarian follicular cyst in a girl with peripheral precocious puberty without adverse reactions, demonstrating its safety and tolerability for suppressing estrogen action.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Functional follicular ovarian cysts are frequently reported in girls with peripheral precocious puberty (PP). These cysts are usually self-limiting and resolve spontaneously. Several drugs like antiestrogens (tamoxifen) and new aromatase inhibitors are seldom used for treatment. Here we report a girl with peripheral PP who presented with unilateral enlargement of the ovary and a recurrent autonomous ovarian cyst. No skin pigmentation or bone anomaly was noted. The patient was successfully treated with anastrozole, a highly selective aromatase inhibitor. No adverse reaction was noted. Anastrozole is a safe and tolerable drug especially used to suppress estrogen action.

My notes (saved in your browser only)

MeSH descriptors

Aromatase Inhibitors Nitriles Ovarian Cysts Triazoles Anastrozole Aromatase Inhibitors Child Female Humans Nitriles Ovarian Cysts Puberty, Precocious Puberty, Precocious Recurrence Triazoles

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (11)

Source provenance

crossref
last seen: 2026-05-17T01:00:14.166772+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:07:04.513278+00:00
unpaywall
last seen: 2026-10-22T06:24:31.118836+00:00
License: CC0 · commercial use OK